@article{4ddacf2b7507465f8dbacb8b659de12e,
title = "Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome",
abstract = "Background: Younger age, male sex and presence of spinal cord lesion(s) increase the risk of conversion from radiologically isolated syndrome (RIS) to relapsing-remitting multiple sclerosis (RRMS). Elevated cerebrospinal fluid (CSF) chitinase-3-like protein 1 (CHI3L1) levels predict conversion from clinically isolated syndrome (CIS) to RRMS. Objective: To evaluate the prognostic value of CSF CHI3L1 in RIS patients for conversion to RRMS. Methods: We compared CSF CHI3L1 concentrations in RIS, CIS, RRMS and symptomatic controls (SCs). We analysed the influence of epidemiological, radiological and CSF parameters on the risk of clinical event. Results: A total of 211 patients (71 RIS, 48 CIS, 50 RRMS and 42 SC) were included. CSF CHI3L1 levels were lower in RIS than in RRMS and higher in RIS with positive CSF versus negative CSF and SC. The presence of at least one spinal cord lesion was the only independent predictor of faster conversion to RRMS. Association of high CSF CHI3L1 levels, positive CSF (presence of oligoclonal bands and/or an elevated IgG index) or four Barkhof criteria with any spinal cord lesion showed a tendency for reduced mean conversion time. Conclusion: CSF CHI3L1 correlates with positive CSF but is not an independent predictor of the risk of conversion from RIS to RRMS.",
keywords = "Multiple sclerosis, biomarkers, cerebrospinal fluid, diagnosis, prognosis, radiologically isolated syndrome",
author = "Eric Thouvenot and Geoffrey Hinsinger and Christophe Demattei and Ugur Uygunoglu and Giovanni Castelnovo and Sophie Pittion-Vouyovitch and Darin Okuda and Orhun Kantarci and Daniel Pelletier and Sylvain Lehmann and Philippe Marin and Aksel Siva and Christine Lebrun",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: E.T. has received honoraria, travel grants or research grants from the following pharmaceutical companies: Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva Pharma. D.O. received lecture fees from Acorda Therapeutics, Genentech, Genzyme and TEVA Neuroscience; consulting and advisory board fees from Celgene, EMD Serono, Genentech, Genzyme and Novartis and research support from Biogen. A.S. has received honoraria for educational presentations internationally and at national meetings and at symposia sponsored by Bayer-Schering AG; Merck Serono; Teva Pharma of Turkey; Biogen Idec/ GenPharma of Turkey and Genzyme; consultation fees or travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Novartis, Genzyme and Roche. C.L. has received honoraria for conferences or advisory boards and travel grants from the following pharmaceutical companies: Biogen, Sanofi Genzyme, Merck, Novartis, Roche and Teva Pharma. G.H., C.D., U.U., G.C., S.P.-V., O.K., D.P., S.L. and P.M. have nothing to disclose. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported by the Centre National de la Recherche Scientifique, The Institut National de la Sant{\'e} et de la Recherche M{\'e}dicale (INSERM), la R{\'e}gion Languedoc Roussillon, the Radiologically Isolated Syndrome Consortium and the Soci{\'e}t{\'e} Fran{\c c}aise de la Scl{\'e}rose en Plaques (SFSEP).",
year = "2019",
month = apr,
day = "1",
doi = "10.1177/1352458518767043",
language = "English (US)",
volume = "25",
pages = "669--677",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",
}